Shares of enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) have earned an average recommendation of “Hold” from the fourteen brokerages that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $11.0455.
A number of research firms recently commented on ENGN. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of enGene in a research note on Tuesday, September 8th. Morgan Stanley downgraded shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective on the stock. in a research note on Thursday, June 18th. Citizens Jmp reissued a “market perform” rating on shares of enGene in a report on Wednesday, September 9th. Wall Street Zen upgraded shares of enGene from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Citigroup reaffirmed a “market perform” rating on shares of enGene in a report on Wednesday, September 9th.
Read Our Latest Analysis on ENGN
enGene Trading Up 2.6%
enGene (NASDAQ:ENGN – Get Free Report) last announced its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.04). On average, research analysts anticipate that enGene will post -1.81 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP acquired a new stake in shares of enGene in the 1st quarter valued at $251,000. Sei Investments Co. acquired a new position in shares of enGene during the 1st quarter worth $409,000. Renaissance Technologies LLC raised its holdings in shares of enGene by 651.1% during the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock worth $1,063,000 after buying an additional 135,318 shares in the last quarter. SR One Capital Management LP bought a new stake in shares of enGene during the 2nd quarter worth $1,293,607. Finally, Elmind Capital LP bought a new stake in shares of enGene during the 4th quarter worth $1,896,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Featured Articles
- Five stocks we like better than enGene
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
